Camp4 Therapeutics Corporation
CAMP
$3.25
-$0.06-1.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.80M | 3.01M | 1.51M | 652.00K | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.80M | 3.01M | 1.51M | 652.00K | 0.00 |
| Cost of Revenue | 39.84M | 40.19M | 39.23M | 38.83M | 39.49M |
| Gross Profit | -36.04M | -37.18M | -37.72M | -38.18M | -39.49M |
| SG&A Expenses | 17.28M | 16.50M | 15.59M | 14.91M | 13.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.12M | 56.69M | 54.82M | 53.74M | 52.53M |
| Operating Income | -53.32M | -53.68M | -53.31M | -53.09M | -52.53M |
| Income Before Tax | -53.40M | -51.78M | -51.77M | -51.79M | -51.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.40 | -51.78 | -51.77 | -51.79 | -51.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.40M | -51.78M | -51.77M | -51.79M | -51.50M |
| EBIT | -53.32M | -53.68M | -53.31M | -53.09M | -52.53M |
| EBITDA | -51.63M | -51.99M | -51.63M | -51.39M | -50.82M |
| EPS Basic | -2.56 | -26.20 | -51.58 | -77.53 | -107.04 |
| Normalized Basic EPS | -1.59 | -16.38 | -32.24 | -48.46 | -66.90 |
| EPS Diluted | -2.56 | -26.20 | -51.58 | -77.53 | -107.04 |
| Normalized Diluted EPS | -1.59 | -16.38 | -32.24 | -48.46 | -66.90 |
| Average Basic Shares Outstanding | 84.84M | 58.12M | 38.44M | 18.76M | 1.94M |
| Average Diluted Shares Outstanding | 84.84M | 58.12M | 38.44M | 18.76M | 1.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |